Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 USD | -0.52% | +20.89% | +8.52% |
02:43pm | Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating | MT |
May. 06 | Transcript : Corvus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.52% | 93.66M | |
+22.81% | 46.81B | |
-1.88% | 41.37B | |
+46.79% | 41.29B | |
-6.20% | 28.87B | |
+11.33% | 26.06B | |
-21.00% | 19.13B | |
+30.73% | 12.39B | |
-0.48% | 12.08B | |
-1.43% | 11.96B |
- Stock Market
- Equities
- CRVS Stock
- News Corvus Pharmaceuticals, Inc.
- Corvus Pharmaceuticals : HC Wainwright Adjusts Corvus Pharmaceuticals' Price Target to $6 from $9.50, Keeps Buy Rating